Técnicas de braquiterapia por cáncer de próstata

Pasteau, 1913 Holm, 1983, Transperineal 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography, J Urol, 130, 283, 10.1016/S0022-5347(17)51108-8 Davis, 2012, American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy, Brachytherapy, 11, 6, 10.1016/j.brachy.2011.07.005 D’Amico, 1998, Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer, JAMA, 280, 969, 10.1001/jama.280.11.969 Cornud, 2012, Endorectal 3D T2-weighted 1 mm-slice thickness MRI for prostate cancer staging at 1. 5Tesla: should we reconsider the indirects signs of extracapsular extension according to the D’Amico tumor risk criteria?, Eur J Radiol, 81, e591, 10.1016/j.ejrad.2011.06.056 Cormier, 2013, Peut-on traiter par curiethérapie en monothérapie par grains permanents les patients présentant un cancer de la prostate Gleason 7 ?, Prog Urol, 23, F12 Cosset, 2008, Selecting patients for exclusive permanent implant prostate brachytherapy: the experience of the Paris Institut Curie/Cochin Hospital/Necker Hospital group on 809 patients, Int J Radiat Oncol Biol Phys, 71, 1042, 10.1016/j.ijrobp.2007.11.056 Hinnen, 2010, Long-term biochemical and survival outcome of 921 patients treated with I-125 permanent prostate brachytherapy, Int J Radiat Oncol Biol Phys, 76, 1433, 10.1016/j.ijrobp.2009.03.049 Martens, 2006, Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy, Brachytherapy, 5, 9, 10.1016/j.brachy.2005.12.002 Keyes, 2006, Decline in urinary retention incidence in 805 patients after prostate brachytherapy: the effect of learning curve?, Int J Radiat Oncol Biol Phys, 64, 825, 10.1016/j.ijrobp.2005.04.056 Wallner, 2002, I-125 versus Pd-103 for low-risk prostate cancer: morbidity outcomes from a prospective randomized multicenter trial, Cancer J, 8, 67, 10.1097/00130404-200201000-00012 Allen, 2005, Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity, Int J Radiat Oncol Biol Phys, 62, 981, 10.1016/j.ijrobp.2004.12.068 Nanda, 2014, Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease, Eur Urol, 65, 177, 10.1016/j.eururo.2012.08.070 Blasko, 1991, Transperineal ultrasound-guided implantation of the prostate: morbidity and complications, Scand J Urol Nephrol Suppl, 137, 113 Moran, 2004, Prostate brachytherapy can be performed in selected patients after transurethral resection of the prostate, Int J Radiat Oncol Biol Phys, 59, 392, 10.1016/j.ijrobp.2003.10.013 Kollmeier, 2005, Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy, J Urol, 173, 808, 10.1097/01.ju.0000152698.20487.0e Sylvester, 2007, 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience, Int J Radiat Oncol Biol Phys, 67, 57, 10.1016/j.ijrobp.2006.07.1382 Hughes, 2001, Preexisting histologic evidence of prostatitis is unrelated to postimplant urinary morbidity, Int J Cancer, 96, 79, 10.1002/ijc.10351 Solan, 2009, There is no correlation between erectile dysfunction and dose to penile bulb and neurovascular bundles following real-time low-dose-rate prostate brachytherapy, Int J Radiat Oncol Biol Phys, 73, 1468, 10.1016/j.ijrobp.2008.06.1946 Merrick, 2002, The importance of radiation doses to the penile bulb vs. crura in the development of postbrachytherapy erectile dysfunction, Int J Radiat Oncol Biol Phys, 54, 1055, 10.1016/S0360-3016(02)03031-6 Li, 2001, Prostate brachytherapy in patients with a penile prosthesis, BJU Int, 87, 712, 10.1046/j.1464-410x.2001.02164.x Nguyen, 2002, Urinary morbidity in brachytherapy patients with median lobe hyperplasia, Brachytherapy, 1, 42, 10.1016/S1538-4721(02)00007-7 Wallner, 2000, Prostate brachytherapy in patients with median lobe hyperplasia, Int J Cancer, 90, 152, 10.1002/1097-0215(20000620)90:3<152::AID-IJC5>3.0.CO;2-# Merrick, 2005, Influence of body mass index on biochemical outcome after permanent prostate brachytherapy, Urology, 65, 95, 10.1016/j.urology.2004.08.044 Peters, 2006, Low-dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease, Int J Radiat Oncol Biol Phys, 66, 424, 10.1016/j.ijrobp.2006.05.027 Battermann, 2000, Feasibility of permanent implants for prostate cancer after previous radiotherapy in the true pelvis, Radiother Oncol, 57, 297, 10.1016/S0167-8140(00)00292-9 Merrick, 2005, Monotherapeutic brachytherapy for clinically organ-confined prostate cancer, W V Med J, 101, 168 Narayana, 2005, Randomized trial of high- and low-source strength (125)I prostate seed implants, Int J Radiat Oncol Biol Phys, 61, 44, 10.1016/j.ijrobp.2004.05.001 Aronowitz, 2010, Optimal equations for describing the relationship between prostate volume, number of sources, and total activity in permanent prostate brachytherapy, Am J Clin Oncol, 33, 164, 10.1097/COC.0b013e31819d3684 Hinnen, 2010, Loose seeds versus stranded seeds in I-125 prostate brachytherapy: differences in clinical outcome, Radiother Oncol, 96, 30, 10.1016/j.radonc.2010.02.012 Fagundes, 2004, Transperineal TRUS-guided prostate brachytherapy using loose seeds versus RAPIDStrand: a dosimetric analysis, Brachytherapy, 3, 136, 10.1016/j.brachy.2004.05.006 Reed, 2007, A prospective randomized comparison of stranded vs. loose 125I seeds for prostate brachytherapy, Brachytherapy, 6, 129, 10.1016/j.brachy.2007.01.003 Waterman, 2002, Impact of postimplant edema on V(100) and D(90) in prostate brachytherapy: can implant quality be predicted on day 0?, Int J Radiat Oncol Biol Phys, 53, 610, 10.1016/S0360-3016(02)02751-7 Merrick, 2000, Modified uniform seed loading for prostate brachytherapy: rationale, design, and evaluation, Tech Urol, 6, 78 Nedea, 2005, Extraprostatic seed placement and its effect on seed loss, Cancer J, 11, 147, 10.1097/00130404-200503000-00010 Merrick, 2007, Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy, Eur Urol, 52, 715, 10.1016/j.eururo.2007.02.041 Keyes, 2009, Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients, Int J Radiat Oncol Biol Phys, 73, 1023, 10.1016/j.ijrobp.2008.05.022 Merrick, 2006, Risk factors for the development of prostate brachytherapy related urethral strictures, J Urol, 175, 1376, 10.1016/S0022-5347(05)00681-6 Salembier, 2007, Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy, Radiother Oncol, 83, 3, 10.1016/j.radonc.2007.01.014 Rosenthal, 2011, American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer, Int J Radiat Oncol Biol Phys, 79, 335, 10.1016/j.ijrobp.2010.08.045 Wallner, 2005, High-dose regions versus likelihood of cure after prostate brachytherapy, Int J Radiat Oncol Biol Phys, 62, 170, 10.1016/j.ijrobp.2004.09.021 Williamson, 2005, Recommendations of the American Association of Physicists in Medicine regarding the impact of implementing the 2004 task group 43 report on dose specification for 103Pd and 125I interstitial brachytherapy, Med Phys, 32, 1424, 10.1118/1.1884925 Genebes, 2013, Conventional versus automated implantation of loose seeds in prostate brachytherapy: analysis of dosimetric and clinical results, Int J Radiat Oncol Biol Phys, 87, 651, 10.1016/j.ijrobp.2013.08.010 Speight, 2000, Prostate volume change after radioactive seed implantation: possible benefit of improved dose volume histogram with perioperative steroid, Int J Radiat Oncol Biol Phys, 48, 1461, 10.1016/S0360-3016(00)00798-7 Bice, 1998, Clinical impact of implementing the recommendations of AAPM Task Group 43 on permanent prostate brachytherapy using 125I. American Association of Physicists in Medicine, Int J Radiat Oncol Biol Phys, 40, 1237, 10.1016/S0360-3016(97)00949-8 Zelefsky, 2007, Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation, Int J Radiat Oncol Biol Phys, 67, 327, 10.1016/j.ijrobp.2006.08.056 Merrick, 2002, Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy, Urology, 60, 650, 10.1016/S0090-4295(02)01840-X Snyder, 2001, Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis, Int J Radiat Oncol Biol Phys, 50, 335, 10.1016/S0360-3016(01)01442-0 Smith, 2001, Argon plasma coagulation for rectal bleeding after prostate brachytherapy, Int J Radiat Oncol Biol Phys, 51, 636, 10.1016/S0360-3016(01)01704-7 Tran, 2005, Rectal fistulas after prostate brachytherapy, Int J Radiat Oncol Biol Phys, 63, 150, 10.1016/j.ijrobp.2005.01.021 Potters, 2001, Potency after permanent prostate brachytherapy for localized prostate cancer, Int J Radiat Oncol Biol Phys, 50, 1235, 10.1016/S0360-3016(01)01578-4 Stock, 2000, The effect of disease and treatment-related factors on biopsy results after prostate brachytherapy: implications for treatment optimization, Cancer, 89, 1829, 10.1002/1097-0142(20001015)89:8<1829::AID-CNCR25>3.0.CO;2-9 Merrick, 2002, Prostate-specific antigen spikes after permanent prostate brachytherapy, Int J Radiat Oncol Biol Phys, 54, 450, 10.1016/S0360-3016(02)02948-6 Kuban, 2006, Comparison of biochemical failure definitions for permanent prostate brachytherapy, Int J Radiat Oncol Biol Phys, 65, 1487, 10.1016/j.ijrobp.2006.03.027 Bostancic, 2007, Isotope and patient age predict for PSA spikes after permanent prostate brachytherapy, Int J Radiat Oncol Biol Phys, 68, 1431, 10.1016/j.ijrobp.2007.01.066 Smathers, 1999, Radiation safety parameters following prostate brachytherapy, Int J Radiat Oncol Biol Phys, 45, 397, 10.1016/S0360-3016(99)00168-6 Michalski, 2003, Radiation exposure to family and household members after prostate brachytherapy, Int J Radiat Oncol Biol Phys, 56, 764, 10.1016/S0360-3016(03)00002-6